|
Parkinson Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings indicate that CYP2D6, CYP1A2 and, to a lesser extent CYP3A4, may have a role in protecting against Parkinson's disease induced by MPTP and other potential environmental neurotoxins.
|
8627546 |
1996 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
|
8640913 |
1996 |
|
Bladder Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
|
8640913 |
1996 |
|
Carcinoma of bladder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.
|
8640913 |
1996 |
|
Hepatitis C
|
0.330 |
Biomarker
|
disease |
CTD_human |
In HCV-infected liver, CYP2A6, CYP3A4, and CYP2B1 were overexpressed in hepatocytes with hemosiderin pigmentation.
|
8864187 |
1997 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Expression in the lung of procarcinogen-metabolizing P450 enzymes in the CYP3A subfamily may contribute to the initiation of pulmonary carcinogenesis by agents that require metabolic activation, such as tobacco-derived polycyclic aromatic hydrocarbons.
|
9070608 |
1997 |
|
Hepatoblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A plasmid containing approximately 1 kb of the CYP3A4 regulatory region (which contains several recognised regulatory elements including glucocorticoid responsive elements) coupled to the reporter gene for human secreted placental alkaline phosphatase (SPAP) was transfected into the human hepatoblastoma cell line HepG2.
|
9512926 |
1998 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between CYP3A4 genotype and tumor stage was most pronounced in men diagnosed at a relatively old age who reported no family history of prostate cancer.
|
9719084 |
1998 |
|
Prostatic Neoplasms
|
0.320 |
GeneticVariation
|
group |
BEFREE |
Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
|
9719084 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this group, 46% of men with stage T3/T4 tumors carried CYP3A4-V, whereas only 5% of individuals with stage T1 tumors carried CYP3A4-V (adjusted odds ratio = 9.45; 95% confidence interval = 2.54-35.17; chi2(1) = 12.28; two-sided P<.001).
|
9719084 |
1998 |
|
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our results suggest that mutations in the CYP3A4 gene may influence prostate carcinogenesis.
|
9719084 |
1998 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between CYP3A4 genotype and tumor stage was most pronounced in men diagnosed at a relatively old age who reported no family history of prostate cancer.
|
9719084 |
1998 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that individuals with CYP3A4-W genotype may be at increased risk for treatment-related leukemia and that epipodophyllotoxin metabolism by CYP3A4 may contribute to the secondary cancer risk.
|
9789061 |
1998 |
|
Treatment related leukaemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Association of CYP3A4 genotype with treatment-related leukemia.
|
9789061 |
1998 |
|
leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Nine of 42 de novo leukemias with MLL gene translocations (21%), and 0 of 22 treatment-related leukemias with MLL gene translocations carried the CYP3A4-V (P = 0.016, FET).
|
9789061 |
1998 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These data suggest that individuals with CYP3A4-W genotype may be at increased risk for treatment-related leukemia and that epipodophyllotoxin metabolism by CYP3A4 may contribute to the secondary cancer risk.
|
9789061 |
1998 |
|
Intestinal metaplasia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Western blotting and RT-PCR demonstrated that CYP3A4 protein and mRNA were expressed in the liver and pyloric gland mucosa with intestinal metaplasia, but not in the fundic gland mucosa without intestinal metaplasia.
|
9849581 |
1998 |
|
Liver diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
To further investigate autoantibodies against cytochrome P-450s during alcohol abuse, sera of rats chronically treated with ethanol in the total enteral nutrition model and sera from alcoholics with or without alcohol liver disease and from control subjects were analyzed by enzyme-linked immunosorbent assay and Western blotting for the presence of IgG against rat and human CYP2E1, rat CYP3A1, and human CYP3A4.
|
9927612 |
1999 |
|
Alcohol abuse
|
0.020 |
Biomarker
|
disease |
BEFREE |
Attention should be given to immune toxicity associated with CYP3A4 autoantibodies and cases of alcohol abuse that are accompanied by exposure to drugs and substances that are CYP3A substrates.
|
9927612 |
1999 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP3A4 and CYP3A7 could be induced in HCC-bearing livers.
|
10519413 |
1999 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Men homozygous for the CYP3A4 variant were more likely to present with higher grade and stage of prostate cancer in a recessive model [odds ratio (OR), 1.7; 95% confidence interval (CI), 0.9-3.4].
|
10548319 |
1999 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Men homozygous for the CYP3A4 variant were more likely to present with higher grade and stage of prostate cancer in a recessive model [odds ratio (OR), 1.7; 95% confidence interval (CI), 0.9-3.4].
|
10548319 |
1999 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we estimated the frequency of the CYP3A4 variant in three ethnic groups with different prostate cancer incidence rates.
|
10660343 |
1998 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we estimated the frequency of the CYP3A4 variant in three ethnic groups with different prostate cancer incidence rates.
|
10660343 |
1998 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast to results with HepG2 cells expressing CYP2E1, no increase in GCS-HS mRNA was found with a HepG2 cell line engineered to express human cytochrome P450 3A4.
|
10748080 |
2000 |